Pharma Focus Europe

Helsinn and Angelini Pharma Extend Partnership to Market AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania, and Slovak Republic

Tuesday, May 28, 2024

Helsinn Group, a prominent pharmaceutical company specializing in supportive care, oncology, and dermato-oncology, along with Angelini Pharma, an international pharmaceutical firm under Angelini Industries, have announced the renewal of their Distribution and License Agreement for AULIN® and MESULID® (Nimesulide) in Bulgaria, Czech Republic, Hungary, Poland, Romania, and Slovak Republic. These medications are used for treating acute pain.

Angelini Pharma, expressed satisfaction with the partnership renewal, highlighting shared values of excellence and dedication to providing top-tier service and products.

Helsinn Group, echoed the sentiment, emphasizing the significance of their ongoing collaboration in ensuring patient access to essential treatments. She stressed the importance of their partnership with Angelini in delivering vital healthcare solutions to those in need.

AULIN® MESULID® are non-selective, non-steroidal anti-inflammatory drugs available in various forms, including oral tablets, granules for oral suspension, and gel. They are prescribed for acute pain management and primary dysmenorrhea, with Aulin® gel also indicated for pain relief associated with sprains and acute traumatic tendinitis.

Angelini Industries, the parent company of Angelini Pharma, is a multinational group with a century-long legacy, operating in various sectors including health, industrial technology, and consumer goods. Their commitment to research and development, coupled with a deep understanding of global markets, positions them as a leader in their field.



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024